The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: One-third of patients with rheumatoid arthritis show inadequate response to tumor necrosis factor α (TNF-α) inhibitors; little guidance on choosing the next treatment exists. OBJECTIVE: To compare the efficacy of a non-TNF-targeted biologic (non-TNF) vs a second anti-TNF drug for patients with insufficient response to a TNF inhibitor. DESIGN, SETTING, AND PARTICIPANTS: A total of 300 patients (conducted between 2009-2012) with rheumatoid arthritis, with persistent disease activity (disease activity score in 28 joints-erythrocyte sedimentation rate [DAS28-ESR] ≥ 3.2 [range, 0-9.3]) and an insufficient response to anti-TNF therapy were included in a 52-week multicenter, pragmatic, open-label randomized clinical trial. The final follow-up date was in August 2013. INTERVENTIONS: Patients were randomly assigned (1:1) to receive a non-TNF-targeted biologic agent or an anti-TNF that differed from their previous treatment. The choice of the biologic prescribed within each randomized group was left to the treating clinician. MAIN OUTCOMES AND MEASURES: The primary outcome was the proportion of patients with good or moderate response according to the European League Against Rheumatism (EULAR) scale at week 24. Secondary outcomes included the EULAR response at weeks 12 and 52; at weeks 12, 24, and 52; DAS28ESR, low disease activity (DAS28 ≤3.2), remission (DAS28 ≤2.6); serious adverse events; and serious infections. RESULTS: Of the 300 randomized patients (243 [83.2%] women; mean [SD] age, 57.1 [12.2] years; baseline DAS28-ESR, 5.1 [1.1]), 269 (89.7%) completed the study. At week 24, 101 of 146 patients (69%) in the non-TNF group and 76 (52%) in the second anti-TNF group achieved a good or moderate EULAR response (OR, 2.06; 95% CI, 1.27-3.37; P = .004, with imputation of missing data; absolute difference, 17.2%; 95% CI, 6.2% to 28.2%). The DAS28-ESR was lower in the non-TNF group than in the second anti-TNF group (mean difference adjusted for baseline differences, -0.43; 95% CI, -0.72 to -0.14; P = .004). At weeks 24 and 52, more patients in the non-TNF group vs the second anti-TNF group showed low disease activity (45% vs 28% at week 24; OR, 2.09; 95% CI, 1.27 to 3.43; P = .004 and 41% vs 23% at week 52; OR, 2.26; 95% CI, 1.33 to 3.86; P = .003). CONCLUSIONS AND RELEVANCE: Among patients with rheumatoid arthritis previously treated with anti-TNF drugs but with inadequate primary response, a non-TNF biologic agent was more effective in achieving a good or moderate disease activity response at 24 weeks than was the second anti-TNF medication. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01000441.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Twisk, J., de Boer, M., de Vente, W., & Heymans, M. (2013) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2013.03.017 · Cited by 568
Cited by
Smolen, J. S., Landewé, R. B. M., Bijlsma, J. W. J., Burmester, G. R., Dougados, M., Kerschbaumer, A., McInnes, I. B., Sepriano, A., van Vollenhoven, R. F., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216655 · Cited by 2,710
Self-citationRingold, S., Angeles‐Han, S. T., Beukelman, T., Lovell, D., Cuello, C. A., Becker, M. L., Colbert, R. A., Feldman, B. M., Ferguson, P. J., Gewanter, H., et al. (2019) · Arthritis Care & Research · doi:10.1002/acr.23870 · Cited by 462
Kerschbaumer, A., Sepriano, A., Smolen, J. S., van der Heijde, D., Dougados, M., van Vollenhoven, R., McInnes, I. B., Bijlsma, J. W. J., Burmester, G. R., de Wit, M., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-216656 · Cited by 293
EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis
Nagy, G., Roodenrijs, N. M. T., Welsing, P. M. J., Kedves, M., Hamar, A., van der Goes, M. C., Kent, A., Bakkers, M., Pchelnikova, P., Blaas, E., et al. (2022) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2021-220973 · Cited by 287
Rheumatoid arthritis: Recent advances on its etiology, role of cytokines and pharmacotherapy
Alam, J., Jantan, I., & Bukhari, S. N. A. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.055 · Cited by 280
Metadata
- Authors
- Gottenberg, J.-E., Brocq, O., Perdriger, A., Lassoued, S., Berthelot, J.-M., Wendling, D., Euller-Ziegler, L., Soubrier, M., Richez, C., Fautrel, B., Constantin, A. L., Mariette, X., Morel, J., Gilson, M., Cormier, G., Salmon, J. H., Rist, S., Lioté, F., Marotte, H., Bonnet, C., Marcelli, C., Sellam, J., Meyer, O., Solau-Gervais, E., Guis, S., Ziza, J.-M., Zarnitsky, C., Chary-Valckenaere, I., Vittecoq, O., Saraux, A., Pers, Y.-M., Gayraud, M., Bolla, G., Claudepierre, P., Ardizzone, M., Dernis, E., Breban, M. A., Fain, O., Balblanc, J.-C., Aberkane, O., Vazel, M., Back, C., Candon, S., Chatenoud, L., Perrodeau, E., Sibilia, J., & Ravaud, P.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2016-09-20
- Volume
- 316
- Issue
- 11
- Pages
- 1172
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2523119278
- Cited by
- 189
- References
- 1
- FWCI
- 24.68
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. https://app.cochat.ai/papers/10.1001/jama.2016.13512
- The paper
- Gottenberg, J.-E., Brocq, O., Perdriger, A., Lassoued, S., Berthelot, J.-M., Wendling, D., Euller-Ziegler, L., Soubrier, M., Richez, C., Fautrel, B., Constantin, A. L., Mariette, X., Morel, J., Gilson, M., Cormier, G., Salmon, J. H., Rist, S., Lioté, F., Marotte, H., . . . Ravaud, P. (2016). Non–TNF-Targeted Biologic vs a Second Anti-TNF Drug to Treat Rheumatoid Arthritis in Patients With Insufficient Response to a First Anti-TNF Drug: A Randomized Clinical Trial. JAMA. https://doi.org/10.1001/jama.2016.13512
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.